Metraipolis › archive › dc_a2fe5eefe459

Unraveling 4-Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition — Europe PMC PMID:42157447

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42157447
DOI: 10.1002/acn3.70430
License (as archived): solo-consultazione
Archived: 2026-11-01T15:17:47.056Z
SHA-256 of the archived text: 2d4d208a9c5e6b30bf49b49df16cb9cf5eb5bc228c04883b37dc99749d14c012
Stable URL of this page: https://metraipolis.com/documento/dc_a2fe5eefe459

How to cite

Unraveling 4-Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition — Europe PMC PMID:42157447 — Europe PMC (en), https://europepmc.org/article/MED/42157447 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a2fe5eefe459 (Metraipolis archive dc_a2fe5eefe459, sha256 2d4d208a9c5e6b30bf49b49df16cb9cf5eb5bc228c04883b37dc99749d14c012)

BibTeX

@misc{dca2fe5eefe459,
  title = {Unraveling 4-Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition — Europe PMC PMID:42157447},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42157447},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a2fe5eefe459; sha256 2d4d208a9c5e6b30bf49b49df16cb9cf5eb5bc228c04883b37dc99749d14c012},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42157447. Agents can read the archived copy with the MCP tool read_document.